Recbio First Biotech To Brave A Hong Kong IPO In 2022
mRNA Contender For Omicron?
Chinese vaccine maker Recbio hopes an IPO in Hong Kong will bring investor attention to its mRNA COVID vaccine with potential against the Omicron variant.
You may also be interested in...
In a vote of confidence, investors predict Shanghai IPOs to rise in 2022, while sluggish share performances in Hong Kong have made a public listing there more “a liquidity rather than an exit event.”
Two Chinese firms join forces to develop mRNA vaccines; UK and India resolve issues over the travel of vaccinated individuals; and Scrip speaks to the CEO of a Canadian firm developing mRNA vaccines.
After slashing the prices of their blockbuster drugs to gain wider patient access through China's main reimbursement program, multinationals are now beginning to face increasing challenges from local competitors.